Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.53 |
| ▸ | PIM1 | P11309 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA4 | P22748 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.41 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14897744 | 0.90 | IRAK4 (0.52) | IRAK4PIM1NTRK1 | |
| SCHEMBL20355593 | 0.86 | IRAK4 (0.53) | IRAK4TP53 | |
| SCHEMBL14897701 | 0.84 | IRAK4 (0.49) | IRAK4NTRK1 | |
| SCHEMBL18654583 | 0.84 | IRAK4 (0.53) | IRAK4PIM1NTRK1NTRK3NTRK2 | |
| SCHEMBL14896942 | 0.83 | IRAK4 (0.49) | IRAK4PIM1NTRK1NTRK3NTRK2 | |
| SCHEMBL14896727 | 0.83 | IRAK4 (0.49) | IRAK4PIM1NTRK1NTRK3NTRK2 | |
| SCHEMBL14897225 | 0.83 | IRAK4 (0.48) | IRAK4PIM1NTRK1NTRK3 | |
| SCHEMBL18654582 | 0.81 | IRAK4 (0.48) | IRAK4PIM1NTRK1NTRK3 | |
| SCHEMBL14897235 | 0.80 | IRAK4 (0.49) | IRAK4PIM1NTRK1NTRK3NTRK2 | |
| SCHEMBL16193126 | 0.80 | IRAK4 (0.48) | IRAK4PIM1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2018-07-05 | — | — | US | disclosed |
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | IRAK4 3168/4885PIM1 4551/4885CA12 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.